Table S2.

Exacerbation rate ratios for budesonide/formoterol compared with formoterol in all patients and in the three COPD disease severity groups

Study month	Exacerbation rate ratios
	All patients, n=2,345		Disease severity
			Moderate COPD, n=408		Severe COPD, n=1,325		Very severe COPD, n=612
		P-value		P-value		P-value		P-value
1	−0.48 (−0.62, −0.29)	<0.0001	−0.50 (−0.80, 0.22)	0.1266	−0.48 (−0.67, −0.19)	0.0036	−0.47 (−0.68, −0.11)	0.0152
2	−0.48 (−0.58, −0.35)	<0.0001	−0.39 (−0.68, 0.15)	0.1270	−0.51 (−0.64, −0.32)	<0.0001	−0.48 (−0.64, −0.25)	0.0004
3	−0.46 (−0.55, −0.35)	<0.0001	−0.45 (−0.67, −0.08)	0.0231	−0.49 (−0.61, −0.34)	<0.0001	−0.41 (−0.57, −0.20)	0.0008
4	−0.45 (−0.53, −0.35)	<0.0001	−0.45 (−0.65, −0.14)	0.0091	−0.45 (−0.56, −0.31)	<0.0001	−0.45 (−0.58, −0.28)	<0.0001
5	−0.40 (−0.48, −0.31)	<0.0001	−0.48 (−0.66, −0.21)	0.0021	−0.40 (−0.51, −0.26)	<0.0001	−0.39 (−0.53, −0.22)	<0.0001
6	−0.36 (−0.44, −0.27)	<0.0001	−0.42 (−0.60, −0.15)	0.0055	−0.37 (−0.48, −0.25)	<0.0001	−0.33 (−0.46, −0.16)	0.0004
7	−0.32 (−0.40, −0.23)	<0.0001	−0.41 (−0.59, −0.15)	0.0043	−0.34 (−0.44, −0.21)	<0.0001	−0.27 (−0.41, −0.10)	0.0037
8	−0.29 (−0.37, −0.20)	<0.0001	−0.39 (−0.57, −0.14)	0.0055	−0.31 (−0.42, −0.19)	<0.0001	−0.23 (−0.37, −0.06)	0.0121
9	−0.28 (−0.36, −0.19)	<0.0001	−0.39 (−0.57, −0.14)	0.0045	−0.30 (−0.40, −0.18)	<0.0001	−0.22 (−0.36, −0.05)	0.0145
10	−0.29 (−0.36, −0.20)	<0.0001	−0.44 (−0.59, −0.21)	0.0007	−0.30 (−0.40, −0.18)	<0.0001	−0.23 (−0.36, −0.06)	0.0082
11	−0.28 (−0.35, −0.19)	<0.0001	−0.42 (−0.58, −0.20)	0.0009	−0.28 (−0.38, −0.17)	<0.0001	−0.23 (−0.36, −0.08)	0.0052
12	−0.27 (−0.35, −0.19)	<0.0001	−0.39 (−0.56, −0.17)	0.0017	−0.29 (−0.38, −0.18)	<0.0001	−0.22 (−0.35, −0.07)	0.0063

Note: Data are presented as reduction in the exacerbation rate ratio and 95% confidence intervals.